JP2015044878A5 - - Google Patents

Download PDF

Info

Publication number
JP2015044878A5
JP2015044878A5 JP2014248831A JP2014248831A JP2015044878A5 JP 2015044878 A5 JP2015044878 A5 JP 2015044878A5 JP 2014248831 A JP2014248831 A JP 2014248831A JP 2014248831 A JP2014248831 A JP 2014248831A JP 2015044878 A5 JP2015044878 A5 JP 2015044878A5
Authority
JP
Japan
Prior art keywords
myxoma virus
cancer cells
pharmaceutical composition
composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014248831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015044878A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015044878A publication Critical patent/JP2015044878A/ja
Publication of JP2015044878A5 publication Critical patent/JP2015044878A5/ja
Pending legal-status Critical Current

Links

JP2014248831A 2006-06-01 2014-12-09 癌の処置のための粘液腫ウイルス変異体 Pending JP2015044878A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80364006P 2006-06-01 2006-06-01
US60/803,640 2006-06-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013040387A Division JP5665899B2 (ja) 2006-06-01 2013-03-01 癌の処置のための粘液腫ウイルス変異体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016197808A Division JP2017008105A (ja) 2006-06-01 2016-10-06 癌の処置のための粘液腫ウイルス変異体

Publications (2)

Publication Number Publication Date
JP2015044878A JP2015044878A (ja) 2015-03-12
JP2015044878A5 true JP2015044878A5 (enExample) 2015-04-23

Family

ID=38802246

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009513472A Withdrawn JP2009538935A (ja) 2006-06-01 2007-06-01 癌の処置のための粘液腫ウイルス変異体
JP2013040387A Expired - Fee Related JP5665899B2 (ja) 2006-06-01 2013-03-01 癌の処置のための粘液腫ウイルス変異体
JP2014248831A Pending JP2015044878A (ja) 2006-06-01 2014-12-09 癌の処置のための粘液腫ウイルス変異体
JP2016197808A Pending JP2017008105A (ja) 2006-06-01 2016-10-06 癌の処置のための粘液腫ウイルス変異体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2009513472A Withdrawn JP2009538935A (ja) 2006-06-01 2007-06-01 癌の処置のための粘液腫ウイルス変異体
JP2013040387A Expired - Fee Related JP5665899B2 (ja) 2006-06-01 2013-03-01 癌の処置のための粘液腫ウイルス変異体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016197808A Pending JP2017008105A (ja) 2006-06-01 2016-10-06 癌の処置のための粘液腫ウイルス変異体

Country Status (12)

Country Link
US (3) US8512713B2 (enExample)
EP (3) EP3254694A1 (enExample)
JP (4) JP2009538935A (enExample)
KR (1) KR20090014364A (enExample)
CN (1) CN101460194B (enExample)
AU (1) AU2007256754B2 (enExample)
CA (2) CA2652228C (enExample)
IL (1) IL195297A (enExample)
MX (1) MX2008015265A (enExample)
NZ (1) NZ572893A (enExample)
WO (1) WO2007143548A2 (enExample)
ZA (1) ZA200809769B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007256754B2 (en) 2006-06-01 2012-11-29 Robarts Research Institute Myxoma virus mutants for cancer treatment
FR2946536B1 (fr) * 2009-06-11 2011-07-29 Agronomique Inst Nat Rech Utilisation d'une souche attenuee de myxoma virus comme oncolytique
US12128099B2 (en) 2018-05-25 2024-10-29 Bioventures, Llc Myxoma virus compositions and methods of use
EP3846829A4 (en) * 2018-09-05 2022-09-14 Arizona Board of Regents on behalf of Arizona State University ONCOLYTIC VIRUS PLATFORM FOR THE TREATMENT OF HEMATOLOGICAL CANCER
WO2020106880A1 (en) 2018-11-20 2020-05-28 Bioventures, Llc Cells for the production of viruses and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ518945A (en) 1997-10-09 2007-03-30 Wellstat Biologics Corp Treatment of neoplasms with viruses
ES2153284B1 (es) 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
AU4246900A (en) 1999-04-15 2000-11-02 Pro-Virus, Inc. Treatment of neoplasms with viruses
EP1200595A2 (en) 1999-07-12 2002-05-02 Viron Therapeutics, Inc. Myxoma virus genes for immune modulation
WO2001087324A1 (en) 2000-05-17 2001-11-22 Viron Therapeutics, Inc. Compositions and methods for promoting immunosuppression
DE60209345T2 (de) * 2001-03-08 2006-08-03 Akzo Nobel N.V. Leporipox-basierende vektorvakzine
US7582614B2 (en) * 2003-03-07 2009-09-01 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
NZ550430A (en) 2004-04-27 2009-06-26 Wellstat Biologics Corp Cancer treatment using viruses and camptothecins
DK2388315T3 (da) * 2005-03-07 2014-08-25 Univ Western Ontario Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling
WO2007143545A2 (en) 2006-06-01 2007-12-13 Robarts Research Institute Tnf signaling in myxoma virus treatments
AU2007256754B2 (en) 2006-06-01 2012-11-29 Robarts Research Institute Myxoma virus mutants for cancer treatment
WO2007147118A1 (en) 2006-06-16 2007-12-21 Robarts Research Institute Infection of cells with myxoma virus requires akt activation

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
JP2014141525A5 (enExample)
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
CL2014001792A1 (es) Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades.
IN2015DN00376A (enExample)
BR212016030926U2 (pt) conjugados de alvo e partículas e formulações dos mesmos
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
JP2016518337A5 (enExample)
WO2015031771A3 (en) Administration of kynurenine depleting enzymes for tumor therapy
JP2013155188A5 (enExample)
TN2017000554A1 (en) Novel combination for use in the treatment of cancer
CN111344398A (zh) 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
JP2015044878A5 (enExample)
HUE060496T2 (hu) Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
IL245738A0 (en) Oxindole derivatives, ways of their preparation and their therapeutic use in the treatment of ampk-related diseases
SG11202103097QA (en) Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g